Clinical Trial Update: Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating safety and immunological effects of pembrolizumab in resectable or borderline resectable pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Craig L Slingluff, Jr | Conditions: Pancreatic Cancer | Phase 1, Phase 2 | Status: UNKNOWN